| Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. | |
| | |
MedLine Citation:
|
PMID: 18555706 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: It has recently been reported that serum CA-125 levels may serve as a prognostic indicator of extravesical disease in patients with bladder cancer. This study evaluated the role of CA-125 as a prognostic marker in patients with transitional cell carcinoma of the bladder undergoing radical cystectomy and urinary diversion. METHODS: Ninety-two consecutive patients underwent planned radical cystectomy and urinary diversion with curative intent (2005-2006). Serum CA-125 levels were obtained in all patients and correlations were made to clinical and operative findings and pathological outcomes. Outcomes were evaluated with regard to normal vs. abnormal CA-125 values and with regard to absolute values of CA-125 levels. Results were also stratified by short-term recurrence rates. RESULTS: Mean CA-125 values varied significantly by pathological stage and by resectability. No patient (0/56) with organ-confined disease (<or= pT2N0) had an abnormal CA-125, and only 1 patient (1/75 = 1.3%) with <or= pT3N0 disease had an abnormal value. Conversely, 35% of patients with regionally-advanced disease (pT4 or N+) had an elevated CA-125, and all patients with unresectable disease (5/5) had an elevated value. In addition, patients with abnormal values of CA-125 (i.e., <35 U/ml) had a significantly higher upstaging rate compared to non-upstaged patients (18.8% vs. 3.5%, respectively; P = 0.0233). As well, patients with CA-125 levels <15 U/ml had a significantly higher upstaging rate compared with non-upstaged patients (53.1% vs. 15.8%, respectively; P = 0.0005). At a mean follow-up of 15 months (median = 14 months), patients with T2/T3N0 disease who recurred had a higher mean value than patients with pT2/T3 disease who did not recur (20.1 vs. 10.8 U/ml). CONCLUSIONS: Serum CA-125 levels may serve as a useful predictor of pathological outcomes in patients undergoing cystectomy for urothelial carcinoma of the bladder. Further studies will be carried out to determine the predictability of CA-125 on long-term recurrence and survival rates, and to evaluate the utility of CA-125 as a marker for disease response in patients with recurrent or advanced disease undergoing systemic therapy. |
| | |
Authors:
|
Erik J Kouba; Aaron Lentz; Eric M Wallen; Raj S Pruthi |
Related Documents
:
|
1965306 - Lavage versus serum measurements of lysozyme, angiotensin converting enzyme and other i... 12893196 - Preoperative diagnosis of malignant transformation arising from mature cystic teratoma ... 7201746 - Serum lactate dehydrogenase isoenzyme 1 in patients with advanced testicular cancer. 2875856 - Serum gamma-glutamyl transpeptidase activity in patients receiving chronic phenytoin th... 19764586 - Middle ear tuberculosis: diagnostic criteria. 1257706 - Enzymes in intestinal mucosa from patients with rheumatoid diseases. |
Publication Detail:
|
Type: Journal Article Date: 2008-06-16 |
Journal Detail:
|
Title: Urologic oncology Volume: 27 ISSN: 1873-2496 ISO Abbreviation: Urol. Oncol. Publication Date: 2009 Sep-Oct |
Date Detail:
|
Created Date: 2009-09-01 Completed Date: 2009-11-17 Revised Date: 2010-03-18 |
Medline Journal Info:
|
Nlm Unique ID: 9805460 Medline TA: Urol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 486-90 Citation Subset: IM |
Affiliation:
|
Division of Urologic Surgery and the Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged CA-125 Antigen / blood* Carcinoma, Transitional Cell / blood*, pathology, surgery Cystectomy Female Humans Immunoassay Male Middle Aged Neoplasm Recurrence, Local / blood, pathology Neoplasm Staging Prognosis Sensitivity and Specificity Tumor Markers, Biological / blood* Urinary Bladder Neoplasms / blood*, pathology, surgery |
| Chemical | |
Reg. No./Substance:
|
0/CA-125 Antigen; 0/Tumor Markers, Biological |
| Comments/Corrections | |
Comment In:
|
Urol Oncol. 2010 Mar-Apr;28(2):226
[PMID:
20056459
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Up-regulation of exploratory tendencies does not enhance general learning abilities in juvenile or y...
Next Document: XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladd...